Helix BioPharma Corp. receives approval for the Extension of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing

 March 3, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, announces that, further to its news release dated February 21, 2025, the Annual General and Special Meeting (the “Meeting”) for the year ended July 31, 2024 has been extended to March 26, 2025 to provide additional time to seek shareholder approval with ...